California Presses Forward In Fight To Regulate Pharma
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
Drug Costs
621-640 of 711 results
-
-
The Orphan Drug Machine
Drugmakers Help Turn Patients With Rare Diseases Into D.C. Lobbyists
Amplifying the "patient voice," those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
-
Trump’s Promise To Rein In Drug Prices Could Open Floodgate To Importation Laws
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
By Rachel Bluth -
GAO To Launch Investigation Of FDA’s Orphan Drug Program
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
-
Prescription Drug Costs Are On The Rise; So Are The TV Ads Promoting Them
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
By Bruce Horovitz and Julie Appleby -
Cholesterol Drug Prevents Heart Attacks — But It Doesn’t Come Cheap
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
By Liz Szabo -
$89,000 Orphan Drug Gets A New Owner — And Likely A New Price
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
-
Treating Cancer: Hope Vs. Hype
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
By Liz Szabo -
Repeal & Replace Watch
Trump, Dems Look For Common Ground On Drug Prices
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
-
Three Key Senators Ask GAO To Investigate Possible Abuses Of The Orphan Drug Act
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
By Sarah Jane Tribble and Sydney Lupkin -
Patient Advocacy Groups Rake In Donations From Pharma
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
By Emily Kopp -
The Orphan Drug Machine
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
By Sarah Jane Tribble and Sydney Lupkin -
Repeal & Replace Watch
Former FDA Chief Cites 5 Things To Watch On Drug Approvals And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
By Sydney Lupkin and Sarah Jane Tribble -
The Orphan Drug Machine
Drugmaker Marathon ‘Pausing’ Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
By Sarah Jane Tribble and Sydney Lupkin -
Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
-
Drugmaker Kaleo Raises Price Of Lifesaving Drug By Thousands
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
-
Drug Prices, Opioids, And Obamacare: A Conversation With Assemblyman Jim Wood
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
-
The Orphan Drug Machine
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
By Sarah Jane Tribble and Sydney Lupkin -
The Orphan Drug Machine
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
By Sarah Jane Tribble and Sydney Lupkin -
The Orphan Drug Machine
Timeline: The Orphan Drug Act
Follow the twists and turns of the orphan drug industry over the past three decades.